MCL1 and cancer: Strikingly, the list of PSODs included several genes that can be inhibited by compounds either in pre-clinical development or already in clinical use for other cancers, such as CCND2, IRF4, MDM2, and MCL1. PEL is a very rare disease, which complicates clinical trial design.